1 **Molecular epidemiology of *Escherichia coli* producing CTX-M and plasmid**
2 **AmpC-type β -lactamases from dairy farms identifies a dominant plasmid**
3 **encoding CTX-M-32 but no evidence for transmission to humans in the same**
4 **geographical region**

5

6 Jacqueline FINDLAY¹, Oliver MOUNSEY¹, Winnie W.Y. LEE¹, Nerissa NEWBOLD^{1,2},
7 Katy MORLEY², Hannah SCHUBERT², Virginia C. GOULD^{1,2}, Tristan A. COGAN²,
8 Kristen K. REYHER², Matthew B. AVISON^{1*}

9

10 ¹School of Cellular & Molecular Medicine, Biomedical Sciences Building, University
11 of Bristol, University Walk, Bristol, UK.

12 ²Bristol Veterinary School, University of Bristol, Langford, UK.

13

14

15 *To whom correspondence should be addressed: bimba@bris.ac.uk.

16

17

18 Running heading: Cefotaxime-resistant *E. coli* from dairy farms

19 Abstract

20 Third-generation cephalosporin resistance (3GC-R) in *Escherichia coli* is a rising
 21 problem in human and farmed animal populations. We conducted whole genome
 22 sequencing analysis of 138 representative 3GC-R isolates previously collected from
 23 dairy farms in South West England and confirmed by PCR to carry acquired 3GC-R
 24 genes. This analysis identified *bla*_{CTX-M} (131 isolates: encoding CTX-M-1, -14, -15, -
 25 32 and the novel variant, CTX-M-214), *bla*_{CMY-2} (6 isolates) and *bla*_{DHA-1} (one isolate).
 26 A highly conserved plasmid was identified in 73 isolates, representing 27 *E. coli*
 27 sequence types. This novel ~220 kb IncHI2 plasmid carrying *bla*_{CTX-M-32} was
 28 sequenced to closure and designated pMOO-32. It was found experimentally to be
 29 stable in cattle and human transconjugant *E. coli* even in the absence of selective
 30 pressure and was found by multiplex PCR to be present on 26 study farms
 31 representing a remarkable range of transmission over 1500 square kilometres.
 32 However, the plasmid was not found amongst human urinary *E. coli* we have
 33 recently characterised from people living in the same geographical location, collected
 34 in parallel with farm sampling. There were close relatives of two *bla*_{CTX-M} plasmids
 35 circulating amongst eight human and two cattle isolates, and a closely related *bla*<sub>CMY-
 36 2</sub> plasmid found in one cattle and one human isolate. However, phylogenetic
 37 evidence of recent sharing of 3GC-R strains between farms and humans in the same
 38 region was not found.

39 Importance

40 Third-generation cephalosporins (3GCs) are critically important antibacterials and
 41 3GC-resistance (3GC-R) threatens human health, particularly in the context of
 42 opportunistic pathogens such as *Escherichia coli*. There is some evidence for
 43 zoonotic transmission of 3GC-R *E. coli* through food, but little work has been done

44 examining possible transmission (e.g. via interaction of people with the local near-
 45 farm environment). We characterised acquired 3GC-R *E. coli* found on dairy farms in
 46 a geographically restricted region of the United Kingdom and compared these with *E.*
 47 *coli* from people living in the same region, collected in parallel. Whilst there is strong
 48 evidence for recent farm-to-farm transmission of 3GC-R strains and plasmids –
 49 including one epidemic plasmid that has a remarkable capacity to transmit – there
 50 was no evidence that 3GC-R found on study farms had a significant impact on
 51 circulating 3GC-R *E. coli* strains or plasmids in the local human population.

52 Introduction

53 Third-generation cephalosporin-resistant (3GC-R) *Escherichia coli* have been
 54 increasingly reported in both animal and human populations and are considered
 55 pathogens of major concern for humans (1,2). 3GCs such as cefotaxime and
 56 ceftazidime have been listed by the World Health Organisation (WHO) as “highest-
 57 priority critically important antimicrobials” (HP-CIAs) because of their importance for
 58 human health (3). Resistance to 3GCs in *E. coli* can be caused by several
 59 mechanisms but is primarily attributed to the acquisition of Extended Spectrum β -
 60 Lactamases (ESBLs) or plasmid-mediated AmpC β -lactamases (pAmpCs) (4).
 61 Plasmids encoding ESBLs and pAmpCs frequently harbour additional resistance
 62 genes and so can present a significant therapeutic challenge (5). In recent years, the
 63 promotion and implementation of the ‘One Health’ approach in antimicrobial
 64 resistance by the WHO has emphasised the importance of surveillance in both
 65 animal and human populations and has highlighted gaps in this knowledge (6). In
 66 humans it has been well established in numerous global studies that certain *E. coli*
 67 lineages (e.g. *bla*_{CTX-M}-encoding ST131) play a major role in the dissemination of
 68 ESBL genes, however such a depth of information does not exist for isolates from
 69 animal populations (2). Human-associated pandemic lineages have been reported in
 70 animal populations albeit to a much lesser extent than in human populations (7).

71 In humans, *bla*_{CTX-M} variants are the globally dominant ESBL type with some variants
 72 exhibiting geographical associations (e.g. *bla*_{CTX-M-15} in Europe and North America
 73 and *bla*_{CTX-M-14} in Asia) (2). Transmission of ESBLs occurs largely through horizontal
 74 gene transfer, with conjugative IncF plasmids being reported as the dominant
 75 vehicles for *bla*_{CTX-M} genes (8,9). Previous studies using typing methodologies
 76 including WGS have suggested transmission of both strains and ESBL plasmids

77 across animal and human populations (10,11). Epidemic plasmids have been
78 reported across different host populations and in multiple countries (12). For
79 example, one epidemic plasmid type – pCT, encoding *bla*_{CTX-M-14} – was identified in
80 cattle and human *E. coli* isolates in England and found to exist in human isolates
81 from several countries across 3 continents (12).

82 Antimicrobial use in food animals may provide selective pressure for resistance
83 genes/plasmids which could theoretically be spread to humans (13). However,
84 recent reports suggest that such transmission is limited, at least in the UK (14). In
85 dairy farming, antibiotics are used both therapeutically in the treatment of common
86 infections such as mastitis, and preventatively. For example, in so-called dry cow
87 therapy, an antibacterial preparation inserted into a cow's udder between lactations
88 to prevent mastitis (15). A survey of dairy farms in England and Wales in 2012
89 revealed that the fourth-generation cephalosporin (4GC) cefquinome (another HP-
90 CIA) was the most used dry cow therapy treatment (16). By 2017, however, only
91 5.3% of total dry cow therapy active ingredients were HP-CIAs. Indeed, there has
92 been a significant decline in the use of HP-CIAs on dairy farms in the UK in recent
93 years (17).

94 Recently, we reported a survey of 53 dairy farms located in South West England
95 where we investigated the prevalence of 3GC-R *E. coli* (18). From 1226 such
96 isolates, PCR analysis confirmed that 648/1226 (52.7%) carried *bla*_{CTX-M} and
97 13/1226 (1.1%) carried a pAmpC gene. The remaining 566/1226 (46.2%) isolates did
98 not carry any putative acquired 3GC-R gene, and a subsequent analysis confirmed
99 that hyper-production of the chromosomally encoded AmpC β -lactamase was the
100 mechanism of 3GC-R in these isolates (19).

The study reported here aimed to characterise, using WGS, representative *bla*_{CTX-M} and pAmpC-positive *E. coli* isolates collected on dairy farms during our earlier surveillance study (18). Furthermore, our aim was to compare these isolates at strain and plasmid-encoded 3GC-R gene level with *bla*_{CTX-M} and pAmpC positive urinary *E. coli* isolates (20) collected from humans living in the same 50 x 50 km region that was the location of the majority of dairy farms under study.

Results and Discussion

WGS analysis of *E. coli* carrying acquired 3GC-R genes from dairy farms

One hundred and thirty-eight representative isolates, PCR-positive for *bla*_{CTX-M} or pAmpC genes (18) and chosen to give coverage of all 42 farms positive for acquired 3GC-R genes, were subjected to WGS (**Table 1**). *bla*_{CTX-M-32}, encoding a group 1 enzyme first described in a human clinical isolate in 2004 (21), was the most common 3GC-R gene identified and was found in 79/138 sequenced isolates encompassing 27 *E. coli* sequence types (STs) from 25 farms. Other 3GC-R genes identified were: *bla*_{CTX-M-14} (18 isolates, 6 STs from 9 farms), *bla*_{CTX-M-1} (16 isolates, 8 STs from 6 farms), *bla*_{CTX-M-15} (16 isolates, 5 STs from 10 farms), *bla*_{CMY-2} (6 isolates, 3 STs from 3 farms), *bla*_{CTX-M-214} (3 isolates, 2 STs from 3 farms) plus one isolate harbouring *bla*_{DHA-1} and one isolate having both *bla*_{CTX-M-1} and *bla*_{CTX-M-14}. CTX-M-214 (GenBank Accession No. MH121688) is a novel CTX-M-9 variant, first identified in this study, which differs from CTX-M-9 by a single amino acid, Ala112Thr. In all three isolates encoding *bla*_{CTX-M-214}, the gene was identified on a contig which also encoded an IncI-ST26 plasmid replicon as well as *aadA2*, *sul1*, and *dfrA16*.

Identification and characterisation of pMOO-32

Following observations of the high prevalence of *bla*_{CTX-M-32}, a search for common plasmid replicon types was conducted which revealed an IncHI2-ST2 replicon in almost all the sequenced *bla*_{CTX-M-32}-positive isolates. Transconjugations were attempted into *E. coli* DH5α using *bla*_{CTX-M-32}-positive farm isolate DK as donor (**Table 2**). One successful transconjugant was sent for WGS employing both long and short read methodologies to sequence the plasmid to closure. pMOO-32 is a 226,022-bp conjugative plasmid belonging to the ST2-IncHI2 incompatibility group, harbouring *repHI2* and *repHI2A* replication genes. It contains 245 putative ORFs and has a GC content of 45.5% (**Figure 1**). pMOO-32 encodes the following antimicrobial resistance genes: *bla*_{CTX-M-32}, *strA*, *strB*, *aph(6)-Ic*, *aph(3')-IIa* and *tetB* as well as genes encoding resistance to the heavy metal compound, tellurite (*terABCDEFWXYZ*) and a HipAB type II toxin-antitoxin system along with a second partial system (*higB* toxin gene). *bla*_{CTX-M-32} is encoded downstream of an *ISEcp1* element within which there is an *ISKpn26* insertion encoded in the opposite orientation (**Figure 2**). This same genetic environment was also observed in 4 *bla*_{CTX-M-32}-positive but IncHI2 plasmid-negative ST10 isolates collected from 2 farms. There were 2 additional IncHI2 plasmid-negative ST765 isolates, both from the same farm, that carried *bla*_{CTX-M-32} where the immediate genetic environment differed by a truncation in *ISEcp1*.

Transconjugation attempts using the pMOO-32-positive farm isolate DK as donor into a 3GC-susceptible (3GC-S) cattle ST88 *E. coli* isolated from one of the study farms (18) as well as into a 3GC-S human urinary ST1193 *E. coli* isolate (20) were both successful (**Table 2**). ST1193 was selected as a recently described fluoroquinolone-resistant global clone, often implicated as a cause of human

infections (22), whilst ST88 was selected as a particularly prevalent ST among cattle isolates (23). Antimicrobial disc testing showed that the pMOO-32-carrying donor was, as expected from the genotype, resistant to ampicillin, cefotaxime, cefepime, aztreonam, streptomycin, neomycin, and tetracycline. The cattle ST88 and human ST1193 transconjugants were, additional to their starting wild-type resistance profile, resistant to cefotaxime, cefepime and aztreonam. These results (**Table 2**) are indicative of the functionality of the *bla*_{CTX-M-32} gene harboured by pMOO-32.

Epidemiology of pMOO-32-like plasmids on farms

The complete nucleotide sequence of pMOO-32 was submitted to GenBank under accession number MK169211. Using this sequence as a reference, sequencing reads from all 73 isolates positive for *bla*_{CTX-M-32} and the IncHI2 replicon were mapped; this indicated that the plasmids exhibited 94-100% identity to the reference sequence. Any differences could be attributed to a loss or gain of mobile genetic elements, but no major rearrangements were observed to the plasmid backbone or changes to resistance gene content. These 73 isolates carrying pMOO-32-like plasmids comprised 27 *E. coli* STs. On 10 farms, pMOO-32-like plasmids were found in isolates of more than one ST. The most frequently identified STs were ST69 and ST10, found in 18 isolates from 7 farms, and 6 isolates from 4 farms, respectively. Therefore, we conclude that pMOO-32-like plasmids are dominant in this study area, largely a result of horizontal rather than clonal transmission.

We subsequently designed a multiplex PCR, based on the pMOO-32 sequence, and used it to screen all group 1 *bla*_{CTX-M}-PCR-positive isolates from our study farms (18) not previously subjected to WGS for the presence of pMOO-32-like plasmids. It was

found that 26/53 (49.1%) farms within our study area tested positive for the presence of a pMOO-32-like plasmid using this test. The origins and geographical reach of pMOO-32 remain to be established, but all positive farms were located in a 40 x 40 km sub-region of the wider study area, where 26/33 farms were positive, suggesting that the plasmid remained geographically confined at the time of sample collection.

We hypothesised that the observed dominance of pMOO-32-like plasmids could be a consequence of the HipAB-type II toxin-antitoxin system found on the plasmid, leading to persistence even in the absence of antibacterial selective pressure. Growth curve assays indicated a 12-40% fitness cost (reduction in OD₆₀₀) of pMOO-32 carriage in *E. coli* DH5α at the end of the exponential growth phase in M9 minimal medium (data not shown). However, despite this cost in growth terms, pMOO-32 was stably maintained over 10 days of passaging in the absence of antibiotic pressure in the farm isolates, their respective DH5α transconjugants, and the human and cattle *E. coli* isolate transconjugants tested.

No evidence for recent sharing of 3GC-R *E. coli* and limited evidence for recent sharing of 3GC-R *E. coli* plasmids between humans and dairy farms

The ability of pMOO-32 to readily transfer into human urinary *E. coli* ST1193 (**Table 2**) and be maintained in the absence of antimicrobial pressure indicates the zoonotic potential of this plasmid. We next aimed to see if there was evidence of recent sharing of 3GC-R isolates or plasmids, including pMOO-32, between dairy farms and humans living in the same geographical region as the farms. To do this, we compared WGS data from farm isolates described above with data from human urinary *E. coli* collected in parallel within the same 50 x 50 km geographical region

(20). Since 10 dairy farms under study here lie outside the 50 x 50 km region (18), isolates from these farms were excluded.

Core genome phylogenetic analysis of 324 sequenced (112 dairy farm and 212 human) *E. coli* isolates carrying acquired 3GC-R genes collected within the target region (**Figure 3**) revealed only four STs including examples of both farm and human isolates. In no case was the single nucleotide polymorphism (SNP) difference between any pair of human and farm isolate core genomes suggestive of recent transmission. ST10 was the closest (≥ 205 SNPs different between human and cattle isolates; **Figure 3** insert); the others were ST540 (929 SNPs different), ST58 (≥ 1388 SNPs different) and ST69 (≥ 831 SNPs different). In contrast, there was clear evidence of recent farm-to-farm transmission of isolates from multiple STs (e.g. ST10 and ST69 where, in both cases, there was a 3 SNP minimum distance between pairs of isolates representing two farms) (**Figure 3**). AmpC hyper-producing *E. coli* isolates from these same farms showed a similar pattern: no evidence of strain sharing between dairy farms and humans but strong evidence for recent farm-to-farm transmission (19). We conclude therefore that if humans encounter 3GC-R isolates from farms, such isolates do not readily go on to colonise them and/or cause UTI.

We next considered transmission of plasmid-mediated 3GC-R between farm and human *E. coli* isolates (i.e. those that have caused UTI). We found that 37/107 *bla*_{CTX-M}-positive *E. coli* isolates from farm samples within our 50 x 50 km study region carried *bla*_{CTX-M} variants also seen amongst 189 *bla*_{CTX-M}-positive urinary *E. coli* cultured from people living in the same region during the same time period (20). None of the human isolates carried *bla*_{CTX-M-32} or any plasmid related to pMOO-32. By filtering sequenced isolates by their *bla*_{CTX-M} variants and plasmid replicon types,

plasmids that shared high degrees of sequence identity in farm and human isolates were identified. One IncI1-ST3 plasmid, found in an ST345 farm isolate, harboured *bla*_{CTX-M-1}. Mapping of sequencing reads showed that this plasmid exhibited 100% coverage and 97.5% sequence identity to an unpublished ~106 kb IncI1-ST3 plasmid (pTC_N40607; GenBank Accession No. CP007651) found in *E. coli* obtained from meat/cattle isolates in the USA. Six human urinary *E. coli* isolates representing STs 23, 127, 131, 141 and 2015 harboured *bla*_{CTX-M-1} on a plasmid that exhibited 99.4-100% coverage and 96.4-98.7% identity when sequencing reads were mapped to pTC_N40607.

Another plasmid type - again obtained from a single farm isolate, in this case of ST58 - exhibited 100% coverage and 98.5% identity by read mapping to a published IncK plasmid, pCT (GenBank Accession No. NC_014477). pCT is ~94 kb and harbours *bla*_{CTX-M-14}. pCT-like plasmids have been reported in both human and veterinary *E. coli* isolates across three continents (12, 23). Amongst human urinary *E. coli* isolates found in this study, two also carried pCT-like plasmids. Both isolates were the pandemic clone ST131, and their pCT-like plasmids exhibited 96.4 or 97.2% identity and 100% coverage to pCT.

In terms of plasmids encoding pAmpC genes, we identified a *bla*_{CMY-2} encoding plasmid, p96 (GenBank Accession no. CP023370). This is a ~96 kb IncI1 plasmid derived from an *E. coli* that caused urinary tract infections in dogs in Scotland (24). Mapping analyses showed that one out of seven *bla*_{CMY-2}-carrying human urinary isolates (ST 80) showed 100% coverage and 99.9% identity to p96. An almost identical plasmid was found in one farm isolate (ST1480) that showed 99.6% coverage and 98.9% identity to p96. As with the two *bla*_{CTX-M} plasmids, this *bla*_{CMY-2} encoding plasmid appears to be globally widespread. Blast analysis found *bla*_{CMY-2}

plasmids with >95% coverage and >98% identity to p96 in *E. coli* isolates from humans in Taiwan (25) and chicken meat in the USA (GenBank Accession no. CP048295).

Concluding remarks

Overall, this analysis finds no evidence of recent, direct sharing of *E. coli* between farms and the local human population that have resulted in UTI. However, three farm *E. coli* isolates carried a *bla*_{CTX-M} or *bla*_{CMY-2} plasmid almost identical to one of three plasmids found in urinary *E. coli* in the local human population. However, these three plasmids are known to be widely disseminated in humans and animals across several continents. Furthermore, no human/farm plasmid pair shared 100% identity. So, whilst there is some general evidence of shared circulating plasmids, as reported in a number of recent studies (14,26,27), the overall level of overlap between UK dairy farm and human 3GC-R *E. coli* identified in this study was very small and not suggestive of any novel or recent zoonotic transmission events. In contrast, both recent and sustained farm-to-farm transmission of 3GC-R *E. coli*, and particularly of a newly identified epidemic plasmid pMOO-32 across many different *E. coli* STs and dairy farms, was clearly seen. Identifying the vectors for this transmission will inform interventions that might facilitate a more rapid reduction in 3GC-R *E. coli* on dairy farms.

Experimental

Bacterial isolates, identification, and susceptibility testing

Details of farm sample collection and microbiological analysis has recently been reported (18). In brief, samples of faecally contaminated sites were collected using sterile overshoes on 53 dairy farms located in South West England between January 2017 and December 2018. Samples were plated onto TBX agar (Sigma-Aldrich, Poole, UK) containing 16 mg.L⁻¹ cephalexin. Up to 5 *E. coli* colonies per cephalexin plate were re-plated onto TBX agar containing 2 mg.L⁻¹ cefotaxime to confirm resistance. Presence of acquired 3GC-R genes (*bla*_{CTX-M}, *bla*_{SHV}, *bla*_{CMY-2} and *bla*_{DHA-1}) was confirmed by PCR. Disc susceptibility testing was performed and interpreted according to EUCAST guidelines (28).

Transconjugations

Transconjugations were performed using rifampicin-resistant (Rif-R) *E. coli* DH5α with both human and cattle *E. coli* isolates as the recipients (**Table 3**). Briefly, 1 mL each of overnight broth cultures of donor and recipient cells were mixed in a 3:1 ratio before centrifugation and resuspension in 50 µL of PBS. Five microlitre aliquots were spotted onto LB agar (Oxoid, Basingstoke, UK) plates and incubated at 37°C for 6 h. Growth was collected and resuspended in 100 µL of PBS before being plated on MacConkey agar (Oxoid) plates containing either 32 mg.L⁻¹ rifampicin (for Rif-R *E. coli* DH5α) or 0.5 mg.L⁻¹ ciprofloxacin (for strains HC4 and HG), and 2 mg.L⁻¹ cefotaxime. Transconjugant colonies were screened by PCR.

WGS and analyses and pMOO-32 PCR

Representative isolates were selected for WGS based on resistance phenotype, β-lactamase gene carriage and farm of isolation, as defined previously (18). WGS was

performed by MicrobesNG (<https://microbesng.uk/>) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA) using 2x250 bp paired end reads. Reads were trimmed using Trimmomatic (29) and assembled into contigs using SPAdes 3.13.0 (30) (<http://cab.spbu.ru/software/spades/>). Resistance genes, plasmid replicon types and sequence types (according to the Achtman scheme [31]) were assigned using the ResFinder (32), PlasmidFinder (33), and MLST 2.0 on the Center for Genomic Epidemiology (<http://www.genomicepidemiology.org/>) platform. Enhanced genome sequencing (combining Illumina and MinION reads) was performed by MicrobesNG on one transconjugant and reads were assembled using Unicycler (34). Contigs were annotated using Prokka 1.2 (35).

Reads and assembled contigs were aligned to reference sequences using the progressive Mauve alignment software (36), CLC Genomics Workbench 12 (Qiagen, Manchester, UK), or BWA (37) and SAMtools (38), with variant positions being called using BCFtools (39). pMOO-32 was visualised using the CGView server (40) (http://stothard.afns.ualberta.ca/cgview_server/).

A multiplex PCR, targeting five size-distinguishable regions of pMOO-32, was designed to indicate the presence of pMOO-32-like plasmids (**Table 4**).

Plasmid stability assay

Three representative pMOO-32 PCR-positive isolates, obtained from different farms, and their transconjugant counterparts were subjected to 10 days of serial passaging on non-selective LB agar. After 10 days, colonies were screened for the presence of pMOO-32 by PCR.

319

320 **Fitness cost assay**

321 Fitness cost was assessed by a growth curve assay using M9 minimal medium
322 (Sigma-Aldrich). Rif-R *E. coli* DH5 α and the pMOO-32 transconjugant strain were
323 grown with shaking at 37°C and OD₆₀₀ measurements were taken at hourly intervals.
324 Assays were performed on three biological replicates.

325

326 **Phylogenetic analysis**

327 Sequence alignment and phylogenetic analysis was carried out using the Bioconda
328 environment (41) on the Cloud Infrastructure for Microbial Bioinformatics (CLIMB)
329 (42). The reference sequence was *E. coli* ST131 isolate EC958 complete genome
330 (accession: HG941718). Sequences were first aligned to a closed reference
331 sequence and analysed for SNP differences, whilst omitting insertion and deletion
332 elements, using the Snippy alignment program. Alignment was then focused on
333 regions of the genome found across all isolates, the core genome, using the Snippy-
334 core program, thus eliminating the complicating factors of insertions and deletions
335 (<https://github.com/tseemann/snippy>). Aligned sequences were then used to
336 construct a maximum likelihood phylogenetic tree using RAxML, utilising the
337 GTRCAT model of rate heterogeneity and the software's autoMR and rapid
338 bootstrap to find the best-scoring maximum likelihood tree and including tree branch
339 lengths, defined as the number of base substitutions per site compared (43,44).
340 Finally, phylogenetic trees were illustrated using the web-based Microreact program
341 (45).

342

343

344 **Acknowledgements**

345 Genome sequencing was provided by MicrobesNG (<http://www.microbesng.uk>). We
346 wish to thank all the farmers who participated in this study.

347

348 **Funding**

349 This work was funded by grant NE/N01961X/1 to M.B.A., K.K.R. and T.A.C. and
350 grant BB/T004592/1 to K.K.R and M.B.A. from the Antimicrobial Resistance Cross
351 Council Initiative supported by the seven United Kingdom research councils. WL is
352 supported by a scholarship from the Medical Research Foundation National PhD
353 Training Programme in Antimicrobial Resistance Research (MRF-145-0004-TPG-
354 AVISO)

355

356 **Transparency declaration**

357 The authors declare no conflict of interests. Farming businesses who permitted
358 access to collect the isolates studied here were not involved in the design of this
359 study or in data analysis and were not involved in drafting the manuscript for
360 publication.

361

362 **Author Contributions**

363 Conceived the Study: K.K.R., M.B.A.

364 Collection of Data: J.F., N.N., O.M., K.M., supervised by T.A.C., M.B.A.

Cleaning and Analysis of Data: J.F., O.M., W.L., H.S., V.C.G., supervised by K.K.R.,
M.B.A.

Initial Drafting of Manuscript: J.F., M.B.A.

Corrected and Approved Manuscript: All Authors

References

1. Department of Health. ESBLs – A threat to human and animal health? Report by the Joint Working Group of DARC and ARHAI. 2012. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215180/dh_132534.pdf.
2. Bevan ER, Jones AM, Hawkey PM. 2017. Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype. *J Antimicrob Chemother* 72: 2145-2155.
3. World Health Organisation. Critically important antimicrobials for human medicine: Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. 5th Revision 2016. <http://apps.who.int/iris/bitstream/handle/10665/255027/9789241512220-eng.pdf;jsessionid=7E5054076A3F8ED22FA8C41A51687950?sequence=1>.
4. Carattoli A. 2009. Resistance plasmid families in Enterobacteriaceae. *Antimicrob Agents Chemother* 53:2227-2238.
5. Gupta K, Bhadelia N. 2014. Management of urinary tract infections from multidrug-resistant organisms. *Infect Dis Clin North Am*. 28:49-59.

- 387 6. World Health Organisation. Antimicrobial Resistance. A manual for developing
388 nations action plans. Version 1; February 2016.
389 [http://apps.who.int/iris/bitstream/handle/10665/204470/9789241549530_eng.pdf;jses](http://apps.who.int/iris/bitstream/handle/10665/204470/9789241549530_eng.pdf;jsessionid=3B5EA17EC2A21038D896E2937CA7FAA9?sequence=1)
390 [sionid=3B5EA17EC2A21038D896E2937CA7FAA9?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/204470/9789241549530_eng.pdf;jsessionid=3B5EA17EC2A21038D896E2937CA7FAA9?sequence=1).
- 391 7. Platell JL, Johnson JR, Cobbold RN, Trott DJ. 2011. Multidrug-resistant
392 extraintestinal pathogenic *Escherichia coli* of sequence type ST131 in animals and
393 foods. Vet Microbiol. 153:99-108.
- 394 8. Marcadé G, Deschamps C, Boyd A, Gautier V, Picard B, Branger C, Denamur
395 E, Arlet G. 2009. Replicon typing of plasmids in *Escherichia coli* producing extended-
396 spectrum beta-lactamases. J Antimicrob Chemother. 63:67-71.
- 397 9. Lee MY, Ko KS, Kang CI, Chung DR, Peck KR, Song JH. 2011. High
398 prevalence of CTX-M-15-producing *Klebsiella pneumoniae* isolates in Asian
399 countries: diverse clones and clonal dissemination. Int J Antimicrob Agents. 38:160-
400 163.
- 401 10. de Been M, Lanza VF, de Toro M, Scharringa J, Dohmen W, Du Y, Hu J, Lei
402 Y, Li N, Tooming-Klunderud A, Heederik DJ, Fluit AC, Bonten MJ, Willems RJ, de la
403 Cruz F, van Schaik W. 2014. Dissemination of cephalosporin resistance genes
404 between *Escherichia coli* strains from farm animals and humans by specific plasmid
405 lineages. PLoS Genet. 10:e1004776.
- 406 11. Lazarus B, Paterson DL, Mollinger JL, Rogers BA. 2015. Do human
407 extraintestinal *Escherichia coli* infections resistant to expanded-spectrum
408 cephalosporins originate from food-producing animals? A systematic review. Clin
409 Infect Dis. 60:439-452.

- 410 12. Cottell JL, Webber MA, Coldham NG, Taylor DL, Cerdo-Trraga AM,
411 Hauser H, Thomson NR, Woodward MJ, Piddock LJ. 2011. Complete sequence and
412 molecular epidemiology of IncK epidemic plasmid encoding *bla*_{CTX-M-14}. *Emerg Infect*
413 *Dis.* 17:645-652..
- 414 13. Robinson TP, Wertheim HF, Kakkar M, Kariuki S, Bu D, Price LB. 2016.
415 Animal production and antimicrobial resistance in the clinic. *Lancet.* 387:e1-3.
- 416 14. Ludden C, Raven KE, Jamrozny D, Gouliouris T, Blane B, Coll F, de Goffau M,
417 Naydenova P, Horner C, Hernandez-Garcia J, Wood P, Hadjirin N, Radakovic M,
418 Brown NM, Holmes M, Parkhill J, Peacock SJ. 2019. One Health Genomic
419 Surveillance of *Escherichia coli* Demonstrates Distinct Lineages and Mobile Genetic
420 Elements in Isolates from Humans versus Livestock. *mBio.* 10:e02693-18.
- 421 15. Higham LE, Deakin A, Tivey E, Porteus V, Ridgway S, Rayner AC. 2018. A
422 survey of dairy cow farmers in the United Kingdom: knowledge, attitudes and
423 practices surrounding antimicrobial use and resistance. *Vet Rec.* 183:746.
- 424 16. Brunton LA, Duncan D, Coldham NG, Snow LC, Jones JR. 2012. A survey of
425 antimicrobial usage on dairy farms and waste milk feeding practices in England and
426 Wales. *Vet Rec.* 171:296.
- 427 17. Veterinary Medicines Directorate. UK Veterinary Antibiotic Resistance and
428 Sales Surveillance Report UK-VARSS 2017.
429 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/750811/_1473963-v1-UK-VARSS_2017_Report_FINAL.pdf)
430 [ment_data/file/750811/_1473963-v1-UK-VARSS_2017_Report_FINAL.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/750811/_1473963-v1-UK-VARSS_2017_Report_FINAL.pdf). 2017.
- 431 18. Schubert H, Morley K, Puddy EF, Arbon R, Findlay J, Mounsey O, Gould VC,
432 Vass L, Evans M, Rees GM, Barrett DC, Turner KM, Cogan TA, Avison MB, Reyher
433 KK. 2020. Reduced antibacterial drug resistance and *bla*_{CTX-M} β -lactamase gene

- 434 carriage in cattle-associated *Escherichia coli* at low temperatures, at sites dominated
435 by older animals and on pastureland: implications for surveillance. BioRxiv doi:
436 <https://doi.org/10.1101/778407>. Appl Environ Microbiol (Submitted).
- 437 19. Alzayn M, Findlay J, Schubert H, Mounsey O, Gould VC, Heesom, KJ, Turner
438 KM, Barrett DC, Reyher KK, Avison MB. 2020. Characterisation of AmpC Hyper-
439 Producing *Escherichia coli* from Humans and Dairy Farms Collected in Parallel in the
440 Same Geographical Region. J Antimicrob Chemother (In Press) doi:
441 10.1093/jac/dkaa207.
- 442 20. Findlay J, Gould VC, North P, Bowker KE, Williams MO, MacGowan AP,
443 Avison MB. 2020. Characterization of Cefotaxime-Resistant Urinary *Escherichia coli*
444 From Primary Care in South-West England 2017-18. J Antimicrob Chemother.
445 75:65-71.
- 446 21. Cartelle M, del Mar Tomas M, Molina F, Moure R, Villanueva R, Bou G. 2004.
447 High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32,
448 derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob Agents
449 Chemother. 48:2308-2313.
- 450 22. Johnson TJ, Elnekave E, Miller EA, Munoz-Aguayo J, Flores Figueroa C,
451 Johnston B, Nielson DW, Logue CM, Johnson JR. 2018. Phylogenomic Analysis of
452 Extraintestinal Pathogenic *Escherichia coli* Sequence Type 1193, an Emerging
453 Multidrug-Resistant Clonal Group. Antimicrob Agents Chemother. 63:e01913-18.
- 454 23. Day MJ, Rodríguez I, van Essen-Zandbergen A, Dierikx C, Kadlec K, Schink
455 AK, Wu G, Chattaway MA, DoNascimento V, Wain J, Helmuth R, Guerra B, Schwarz
456 S, Threlfall J, Woodward MJ, Coldham N, Mevius D, Woodford N. 2016. Diversity of
457 STs, plasmids and ESBL genes among *Escherichia coli* from humans, animals and

458 food in Germany, the Netherlands and the UK. J Antimicrob Chemother. 71:1178-
459 1182.

460 24. Wagner S, Lupolova N, Gally DL, Argyle SA. 2017. Convergence of Plasmid
461 Architectures Drives Emergence of Multi-Drug Resistance in a Clonally Diverse
462 *Escherichia coli* Population From a Veterinary Clinical Care Setting. Vet Microbiol
463 211:6-14.

464 25. Lin YT, Pan YJ, Lin TL, Fung CP, Wang JT. 2015. Transfer of CMY-2
465 Cephalosporinase From *Escherichia coli* to Virulent *Klebsiella pneumoniae* Causing
466 a Recurrent Liver Abscess. Antimicrob Agents Chemother 59:5000-5002.

467 26. Pietsch M, Irrgang A, Roschanski N, Brenner Michael G, Hamprecht A, Rieber
468 H, Käsbohrer A, Schwarz S, Rösler U, Kreienbrock L, Pfeifer Y, Fuchs S, Werner G;
469 RESET Study Group. 2018. Whole genome analyses of CMY-2-producing
470 *Escherichia coli* isolates from humans, animals and food in Germany. BMC
471 Genomics. 19:601.

472 27. Valcek A, Roer L, Overballe-Petersen S, Hansen F, Bortolaia V,
473 Leekitcharoenphon P, Korsgaard HB, Seyfarth AM, Hendriksen RS, Hasman H,
474 Hammerum AM. 2019. IncI1 ST3 and IncI1 ST7 plasmids from CTX-M-1-producing
475 *Escherichia coli* obtained from patients with bloodstream infections are closely
476 related to plasmids from *E. coli* of animal origin. J Antimicrob Chemother. 74:2171-
477 2175.

478 28. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters.
479 Version 8.1.
480 [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf)
481 [8.1_Breakpoint_Tables.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf).

- 482 29. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for
483 Illumina sequence data. *Bioinformatics*. 30:2114-2120.
- 484 30. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin
485 VM, Nikolenko SI, Pham S, Pribelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler
486 G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm
487 and its applications to single-cell sequencing. *J Comput Biol*. 19:455-477.
- 488 31. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves
489 PR, Maiden MC, Ochman H, Achtman M. 2006. Sex and virulence in *Escherichia*
490 *coli*: an evolutionary perspective. *Mol Microbiol*. 60:1136-1151
- 491 32. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O,
492 Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance
493 genes. *J Antimicrob Chemother*. 67:2640-2644.
- 494 33. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L,
495 Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using
496 PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents*
497 *Chemother*. 58:3895-3903.
- 498 34. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: Resolving bacterial
499 genome assemblies from short and long sequencing reads. *PLoS Comput Biol*.
500 13:e1005595.
- 501 35. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation.
502 *Bioinformatics*. 30:2068-2069.
- 503 36. Darling AE, Mau B, Perna NT. 2010. progressiveMauve: multiple genome
504 alignment with gene gain, loss and rearrangement. *PLoS One*. 5:e11147.

- 505 37. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-
506 Wheeler transform. *Bioinformatics*. 25:1754-1760.
- 507 38. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G,
508 Abecasis G, Durbin R. 2009. The sequence alignment/Map format and SAMtools.
509 *Bioinformatics*. 25:2978-2079.
- 510 39. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G,
511 Abecasis G, Durbin R. 2009. The sequence alignment/Map format and SAMtools.
512 *Bioinformatics*. 25:2978-2079.
- 513 40. Grant JR, Stothard P. 2008. The CGView Server: a comparative genomics
514 tool for circular genomes. *Nucleic Acids Res*. 2008 36:W181-4.
- 515 41. Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH,
516 Valieris R, Köster J; Bioconda Team. 2018. Bioconda: sustainable and
517 comprehensive software distribution for the life sciences. *Nat Methods*. 15:475-476.
- 518 42. Connor TR, Loman NJ, Thompson S, Smith A, Southgate J, Poplawski R, Bull
519 MJ, Richardson E, Ismail M, Thompson SE, Kitchen C, Guest M, Bakke M,
520 Sheppard SK, Pallen MJ. 2016. CLIMB (the Cloud Infrastructure for Microbial
521 Bioinformatics): an online resource for the medical microbiology community. *Microb*
522 *Genom*. 2:e000086.
- 523 43. Stamatakis A, Ludwig T, Meier H. 2005. RAxML-III: a fast program for
524 maximum likelihood-based inference of large phylogenetic trees. *Bioinformatics*.
525 21:456-463.
- 526 44. Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic
527 analyses with thousands of taxa and mixed models. *Bioinformatics*. 22:2688-2690.

528 45. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ,
529 Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016. Microreact:
530 visualizing and sharing data for genomic epidemiology and phylogeography. *Microb Genom.*
531 2:e000093.

Abundance of acquired 3GC-R mechanisms identified by WGS and number of STs/farms involved														
Total	<i>bla</i> _{CTX-}	STs/	<i>bla</i> _{CTX-}	STs/	<i>bla</i> _{CTX-}	STs/	<i>bla</i> _{CTX-}	STs/	<i>bla</i> _{CTX-}	STs/	<i>bla</i> _{DHA-1}	STs/	<i>bla</i> _{CMY-2}	STs/
isolates/ farms	M-32	farms	M-1	farms	M-14	farms	M-15	farms	M-214	farms		farms		farms
138/42	79	27/25	16 ^a	8/6	18 ^a	6/9	16	5/10	3	2/3	1	1/1	6	3/3

Table 1. Characteristics of 3GC-R 138 isolates subjected WGS.

^aOne isolate harboured both *bla*_{CTX-M-1} and *bla*_{CTX-M-14}.

Antimicrobial Agent	Zone Diameters (mm)													
	<i>E. coli</i> DK	S/I/R	<i>E. coli</i> DH5α	S/I/R	<i>E. coli</i> DH5α TR	S/I/R	<i>E. coli</i> HG	S/I/R	<i>E. coli</i> HG TR	S/I/R	<i>E. coli</i> HC4	S/I/R	<i>E. coli</i> HC4 TR	S/I/R
AMP	<6	R	30	S	<6	R	<6	R	<6	R	20	S	<6	R
CTX	10	R	45	S	18	I	35	S	10	R	34	S	13	R
CAZ	20	I	45	S	30	S	34	S	20	I	32	S	23	S
FEP	19	R	45	S	28	S	28	S	18	R	35	S	24	I
ETP	30	S	45	S	44	S	34	S	33	S	36	S	36	S
ATM	15	R	45	S	24	I	34	S	15	R	35	S	19	R
STR ^a	<6	R	25	S	10	R	<6	R	<6	R	13	R	<6	R
TOB	17	S	28	S	26	S	<6	R	<6	R	18	S	19	S
NEO ^a	8	R	20	S	12	R	<6	R	<6	R	14	I	8	R
TET ^a	<6	R	36	S	<6	R	<6	R	<6	R	30	S	<6	R

Table 2. Disc susceptibility testing of *E. coli* DK and pMOO-32 transconjugants of various *E. coli* recipient strains.

AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ETP, ertapenem; ATM, aztreonam; STR, streptomycin; TOB, tobramycin; NEO, neomycin; TET, tetracycline; TR, pMOO-32 transconjugant.

^aStreptomycin and neomycin sensitivities were determined using tobramycin EUCAST interpretation guidelines, and tetracycline according to guidelines for *Yersinia enterocolitica*.

Isolate	Source/Host	ST	Resistance Genes	Use
DK	Cattle	155	<i>strA</i> , <i>strB</i> , <i>aph(6)-Ic</i> , <i>aph(3')-IIa</i> , <i>tet(B)</i> , <i>bla</i> _{CTX-M-32}	Donor
HC4	Human	1193	<i>aadA5</i> , <i>dfrA17</i> , <i>mdf(A)</i> , <i>sul1</i>	Recipient
HG	Cattle	88	<i>aph(6)-Id</i> , <i>ant(2'')-Ia</i> , <i>aph(3')-Ia</i> , <i>aadA24</i> , <i>aph(3'')-Ib</i> , <i>sul1</i> , <i>sul2</i> , <i>tet(A)</i> , <i>tet(B)</i> , <i>bla</i> _{TEM-1} , <i>bla</i> _{OXA-1} , <i>catA1</i> , <i>floR</i>	Recipient

Table 3. Characteristics of *E. coli* strains used in transconjugation experiments.

Primer	Sequence (5'-3')	Product Size (bp)	Target
aph(3')-IIa_F	TGGCTACCCGTGATATTGCT	642	<i>aph(3')-IIa/aph(6)-Ic</i> junction
aph(6)-Ic_R	CTGGCGGACGGGAAGTATC		
HI2A_F	AGCCTTTCTCACGGTAGCAT	526	HI2 <i>repA</i>
HI2A_R	TTCAATTGTCGGTGAGCGTC		
Tral_F	CGGGAAAAGCTGCACTCAAT	396	<i>tral</i>
Tral_R	AAGACTTTGTGAGCTTGGCG		
TetB_F	TTCAGCGCAATTGATAGGCC	285	<i>tetB</i>
TetB_R	ATCCCACCACCAGCCAATAA		
CTX-M-32_F	TTAGGAAGTGCGCGCTGTA	180	<i>bla</i> _{CTX-M-32}
CTX-M-32_R	CACGGCCATCACTTTACTGG		

Table 4. Primers used for the pMOO-32 multiplex PCR.

Figure 2. The genetic environment of *bla*_{CTX-M-32} in pMOO-32 and other IncHI2 positive, *bla*_{CTX-M-32}-harbouring isolates.

Figure 3. Phylogenetic analysis of *E. coli* from dairy farms and human UTI collected in parallel in a 50 x 50 km region.

Human isolates are noted in orange; cattle isolates are noted in blue. The reference ST131 isolate is noted in black. Certain key STs are highlighted, particularly STs with representatives from human and cattle isolates: ST21 (ST540), ST69, ST58 and ST10. The insert shows a more detailed analysis of ST10 isolates which represents the closest relationship between a human and a cattle isolate: 205 SNPs different across the core genome.